Chemotherapy News and Research

Latest Chemotherapy News and Research

Almac devises new test to detect likelihood of colon cancer recurring

Northern Ireland-based pharmaceutical development company Almac has devised a groundbreaking new test which can detect the likelihood of the recurrence of stage 2 colon cancer in patients who have undergone surgery.

9 Nov 2011

New breast and ovarian cancer vaccine in the pipeline: Study

A new vaccine is being tried clinically to combat tumor cells in a small study of advanced breast and ovarian cancer patients. The results show that there is improvement in overall survival times and stopping the disease for a handful of breast cancer patients.

8 Nov 2011

Older women do not benefit from improvements in breast cancer treatments

The survival rates for older women with breast cancer lag behind younger women diagnosed with the disease, indicating that the elder population may be missing out on improvements in treatment and detection, according to new research from the University of Texas MD Anderson Cancer Center.

8 Nov 2011

New technology can detect toxins in a person's breath

Breathing. Anyone reading this article is doing it right now. But what chemicals are we breathing in, and out? A group of Virginia Tech College of Engineering researchers has published a paper in the journal Environmental Science & Technology that details how to learn just that, using microelectromechanical systems to focus on toxins and everyday impurities that enter the body through the air we intake.

8 Nov 2011

EpiCept reports net loss of $5.4 million for third quarter 2011

EpiCept Corporation today announced operating and financial results for the three and nine months ended September 30, 2011, and provided an update with respect to the Company's key business initiatives.

8 Nov 2011

Bristol-Myers Squibb receives FDA approval for Erbitux to treat head and neck cancer

The U.S. Food and Drug Administration today approved Erbitux (cetuximab) for use with chemotherapy to treat patients with late-stage (metastatic) head and neck cancer.

8 Nov 2011

New data from Pfizer's hematology portfolio to be presented at 53rd ASH annual meeting

Pfizer Oncology will present data on a number of investigational compounds from its hematology portfolio, including new data from bosutinib in chronic myeloid leukemia (CML), inotuzumab in non-Hodgkin lymphoma (NHL), as well as the first presentation of clinical data for PF-04449913, which inhibits Smoothened (SMO), a key component of the Hedgehog pathway.

7 Nov 2011

Research: Nucleolar disruption could destroy cancer cells

DAMAGING a cell's nucleolus could destroy cancer cells by increasing levels of the most important tumour prevention protein, p53, reveals research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool, today.

7 Nov 2011

DSS VistA Chemotherapy Manager goes live at San Francisco VA Medical Center

DSS, Inc., a leading provider of software development, integration, project management, implementation and support of VistA, today announced that its customized VistA Chemotherapy Manager (VCM) system is now live and in production at the San Francisco VA Medical Center.

7 Nov 2011

A.P. Pharma's third quarter net loss increases to $4.2 million

A.P. Pharma, Inc., a specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2011 and highlighted its recent corporate progress.

7 Nov 2011

Pharmacyclics first quarter GAAP net loss increases to $14.5M

Pharmacyclics, Inc. today reported financial results and recent developments for its fiscal first quarter ended September 30, 2011.

7 Nov 2011

PKM2 enzyme has important non-metabolic functions in cancer formation

The embryonic enzyme pyruvate kinase M2 (PKM2) has a well-established role in metabolism and is highly expressed in human cancers. Now, a team led by researchers at the University of Texas MD Anderson Cancer Center reports in advance online publication of the journal Nature that PKM2 has important non-metabolic functions in cancer formation.

7 Nov 2011

Women may not receive adequate fertility preservation advice before breast cancer treatment

Women may not receive adequate information on fertility preservation before breast cancer treatment, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.

7 Nov 2011

Blocking APE1 enzyme could provide new way to kill cancer cells

BLOCKING a key DNA damage repair enzyme, called APE1, could provide a new way to kill cancer cells containing faulty BRCA genes, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.

7 Nov 2011

SJH&MC the first in Southeast Michigan to offer Hyperthermic Intraperitoneal Chemotherapy

A unique treatment involving the use of hot chemotherapy is being offered at St. John Hospital and Medical Center. SJH&MC is the first hospital in Southeast Michigan and one of only approximately 20 centers nationwide to offer the treatment.

5 Nov 2011

Chemotherapy plus radiation improves overall survival for patients with stage II NPC

The combination of chemotherapy and radiation significantly improved the 5-year overall survival of patients with stage II nasopharyngeal carcinoma (NPC), according to a phase III study published Nov. 4 in the Journal of the National Cancer Institute.

5 Nov 2011

Viewpoints: Romney's plan to cut the debt; congressional squabbles on spending; spurning insurers' concerns about new labels

First, eliminate every government program that is not absolutely essential. There are many things government does that we may like but that we do not need. … For example: Repeal ObamaCare, which would save $95 billion in 2016. …Eliminate Title X family planning programs benefiting abortion groups like Planned Parenthood. … Second, return federal programs to the states where innovation, cost management and reduction of fraud and abuse can far exceed what Washington achieves. I will block grant Medicaid and workforce training, saving well over $100 billion in 2016.

5 Nov 2011

MicroRNAs may predict risk of recurrence in post-resection gastric cancer patients

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostics, announces that results from a joint study by researchers at the Institutes of Oncology, Davidoff Center, Rabin Medical Center, Beilinson Hospital and Golda-Hasharon Hospital in Petach-Tikva, Israel show that in post-resection gastric cancer patients microRNAs may serve to predict the risk of recurrence.

4 Nov 2011

GTx third quarter net loss increases to $9.3 million

GTx, Inc. today reported financial results for the third quarter of 2011. The net loss for the quarter ended September 30, 2011 was $9.3 million compared with a net loss of $8.6 million for the quarter ended September 30, 2010, reflecting increased research and development costs in connection with the Company's Ostarine™ and Capesaris™ clinical development programs.

4 Nov 2011